STAT6 (Signal Transducer and Activator of Transcription 6)¹¹ STAT6 (Signal Transducer and Activator of Transcription 6)
A transcription factor activated by IL-4 and IL-13 signaling; when these cytokines bind their receptor, STAT6 becomes phosphorylated, dimerizes, and translocates to the nucleus to switch on genes for IgE production, eosinophil recruitment, and airway remodeling — the cellular signature of allergic disease sits at the center of the Th2 immune axis. The rs167769 variant is located in intron 2 of the STAT6 gene on chromosome 12q13, approximately 1,600 base pairs downstream of its haplotype partner rs324011. Together, these two intronic variants form a functional regulatory unit that controls how much STAT6 protein the cell produces in response to inflammatory signals.

The Mechanism

Deep sequencing of the STAT6 intron 2 regulatory region, published by Schedel et al. 2009²² Schedel et al. 2009
J Allergy Clin Immunol; identified rs167769 among intronic variants modulating STAT6 expression; T alleles of both rs324011 and rs167769 significantly increased STAT6 promoter activity in luciferase reporter assays, revealed that the T allele at rs167769, like the T allele at rs324011, significantly increases STAT6 promoter activity compared to the C allele. When both T alleles are present on the same chromosome — the rs167769-T / rs324011-T haplotype — the upregulation of STAT6 transcription is most pronounced. The precise mechanism for rs167769 is less fully characterized than for rs324011 (which creates a new NF-κB binding site), but the functional assay evidence for both SNPs acting in concert on STAT6 promoter activity is consistent and replicated.

The consequence of elevated STAT6 expression is amplified Th2 signaling downstream: more IgE class switching in B cells, enhanced eosinophil recruitment, and greater IL-4 and IL-13 production in a feed-forward loop. This molecular amplification is measurable as elevated total serum IgE — the circulating antibody class responsible for immediate hypersensitivity reactions — and manifests clinically as increased susceptibility to atopic dermatitis, asthma, allergic rhinitis, and, through a separate mechanism, eosinophilic esophagitis.

The Evidence

The functional and clinical significance of the rs167769/rs324011 haplotype was established in a Taiwanese pediatric cohort by Lee et al. 2015³³ Lee et al. 2015
Taiwan Children Health Study; genotyped STAT6 variants in childhood atopic dermatitis; J Dermatol Sci 2015, which showed the combined two-SNP haplotype was significantly associated with childhood atopic dermatitis at global p=0.0018 — a stronger signal than either variant alone. rs167769 individually showed borderline significance (OR 1.21, 95% CI 0.99–1.49), consistent with its role as a haplotype component rather than an independent major-effect variant.

An important additional phenotype emerged from work on eczema herpeticum (EH) — a dangerous disseminated herpes simplex virus infection that occurs predominantly in atopic dermatitis patients with barrier defects and skewed Th2 immunity. Howell et al. 2011⁴⁴ Howell et al. 2011
J Allergy Clin Immunol; 444 white AD patients genotyped for 10 STAT6 SNPs; studied susceptibility to disseminated viral skin infections found that rs167769 C allele was significantly protective against eczema herpeticum (OR 0.65, 95% CI 0.43–0.98, p=0.027), meaning T allele carriers have elevated risk for this viral complication on top of atopic dermatitis. The strongest STAT6 signal in that study involved a 2-SNP haplotype including rs167769 (24.9% frequency in EH cases vs 9.2% in controls, P=5.17×10⁻⁶), indicating the variant plays a mechanistic role in the impaired antiviral immunity associated with STAT6 overexpression.

In pediatric gastroenterology, Mougey et al. 2021⁵⁵ Mougey et al. 2021
Clin Gastroenterol Hepatol; 73 children with EoE on PPI maintenance therapy found that rs167769 (in high linkage disequilibrium with rs324011 and rs12368672, r²≥0.8) conferred a 2.3- to 2.8-fold increased odds of eosinophilic esophagitis relapse after one year of reduced-dose proton pump inhibitor maintenance. This suggests the STAT6 haplotype is a pharmacogenomic marker for EoE treatment durability.

Practical Implications

For T allele carriers, the elevated STAT6 expression lowers the threshold for Th2 immune activation. Total serum IgE — the most accessible clinical readout of Th2 axis activity — can quantify how active this pathway is and how it responds to interventions. For individuals with confirmed atopic dermatitis, the rs167769-T genotype adds genetic context to the elevated STAT6 tone identified by rs324011-T, reinforcing the biological case for IL-4/IL-13 pathway-directed therapy with dupilumab when disease is moderate to severe.

In eosinophilic esophagitis, T allele carriers who respond initially to PPI therapy should be aware that their STAT6 haplotype is associated with higher relapse rates — this finding supports closer follow-up, consideration of higher PPI maintenance dosing, or earlier escalation to IL-4/IL-13-targeted therapy (dupilumab is FDA-approved for EoE).

The eczema herpeticum data are particularly actionable: T allele carriers with active atopic dermatitis should ensure they have a clear plan for early antiviral treatment (oral acyclovir or valacyclovir) if a disseminated vesicular eruption develops. Prompt antiviral initiation substantially reduces the severity and complications of eczema herpeticum.

Interactions

rs167769 and rs324011 operate in the same functional haplotype block; individuals carrying T alleles at both loci have the highest STAT6 expression of any genotype combination. The combined haplotype interacts additively with downstream pathway variants: IL-13 rs20541-A (hyperactive IL-13 protein) and IL-4Rα rs1801275-G (sensitized receptor) both amplify the same Th2 signaling cascade that elevated STAT6 expression executes. The IL-13 promoter variant rs1800925 is an additional upstream modulator of the same pathway.

About 3 million years ago, a 900-kilobase inversion occurred on chromosome 17q21¹¹ a 900-kilobase inversion occurred on chromosome 17q21
This inversion created two distinct haplotype clades that have been recombinationally suppressed since, accumulating independent sequence variations, creating two distinct evolutionary lineages of the microtubule-associated protein tau (MAPT) gene: H1 and H2. This SNP, rs17649553, is one of several markers that can distinguish between these two haplotypes, which have profoundly different effects on the risk of developing neurodegenerative diseases involving abnormal tau protein deposits.

The MAPT gene encodes tau, a protein primarily expressed in neurons that stabilizes microtubules and supports axonal transport²² stabilizes microtubules and supports axonal transport
Microtubules are the cell's internal transportation system, and tau helps maintain their structure. When tau becomes abnormally phosphorylated and aggregates, it forms neurofibrillary tangles — pathological hallmarks of tauopathies including Alzheimer's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease, and some forms of Parkinson's disease and frontotemporal dementia (FTD).

The Haplotype Structure

Because of the ancient inversion, H1 and H2 exist in complete linkage disequilibrium across nearly 900kb³³ H1 and H2 exist in complete linkage disequilibrium across nearly 900kb
Any SNP in this region can tag the haplotype, as recombination between them has been suppressed for millions of years. The H1 haplotype is evolutionarily dynamic and contains numerous subhaplotypes (H1a, H1b, H1c, etc.), while H2 is more homogeneous. Population distribution is striking: H2 is rare in Africans, almost absent in East Asians, but found at approximately 20% frequency in Europeans⁴⁴ H2 is rare in Africans, almost absent in East Asians, but found at approximately 20% frequency in Europeans
This population-specific distribution suggests selection pressure in European populations.

The Evidence for Parkinson Disease

A 2007 study of 1,762 Parkinson's disease patients and 2,010 controls found a robust association between the H1/H1 diplotype and PD risk (OR 1.46, 95% CI 1.25-1.69, p = 8×10⁻⁷)⁵⁵ A 2007 study of 1,762 Parkinson's disease patients and 2,010 controls found a robust association between the H1/H1 diplotype and PD risk (OR 1.46, 95% CI 1.25-1.69, p = 8×10⁻⁷)
The effect was evident in both familial and sporadic subgroups, men and women, and early- and late-onset disease. A meta-analysis of 23 Caucasian case-control series (7,736 patients, 9,339 controls) estimated an overall OR of 0.78 for H2 versus H1⁶⁶ A meta-analysis of 23 Caucasian case-control series (7,736 patients, 9,339 controls) estimated an overall OR of 0.78 for H2 versus H1
This suggests H2 may be protective against Parkinson's disease.

Progressive Supranuclear Palsy and Other 4R Tauopathies

The association is even stronger for PSP. The H1 haplotype is found in approximately 94% of PSP patients compared to around 78% in healthy adults⁷⁷ The H1 haplotype is found in approximately 94% of PSP patients compared to around 78% in healthy adults
Nearly all PSP patients are H1 homozygotes, though H1 appears necessary but not sufficient to cause disease. PSP is a rare atypical parkinsonian disorder characterized by vertical supranuclear gaze palsy, unprovoked falls, axial rigidity, and cognitive decline, with predominant accumulation of 4-repeat tau in neurons and glia⁸⁸ with predominant accumulation of 4-repeat tau in neurons and glia
The 4R:3R tau isoform ratio appears critical in PSP pathogenesis.

Corticobasal degeneration and Alzheimer's disease also show H1 associations, though the specific subhaplotypes involved differ. The H1c subhaplotype, tagged by rs242557, is specifically associated with increased Alzheimer's disease risk in APOE ε4 non-carriers⁹⁹ The H1c subhaplotype, tagged by rs242557, is specifically associated with increased Alzheimer's disease risk in APOE ε4 non-carriers
Different H1 subhaplotypes confer risk for different tauopathies.

The Pick's Disease Paradox

In a striking reversal, a 2024 study of 338 pathologically confirmed Pick's disease cases found the H2 haplotype associated with increased risk¹⁰¹⁰ a 2024 study of 338 pathologically confirmed Pick's disease cases found the H2 haplotype associated with increased risk
This is opposite to the protective effect seen in PSP and CBD. Pick's disease is a 3-repeat tauopathy characterized by Pick bodies in the frontal and temporal lobes. This finding suggests the H1/H2 polymorphism may affect the balance of 3R and 4R tau isoforms through alternative splicing of exon 10¹¹¹¹ the H1/H2 polymorphism may affect the balance of 3R and 4R tau isoforms through alternative splicing of exon 10
H1 may promote 4R tau, while H2 may favor 3R tau.

Frontotemporal Dementia

The majority of genetic FTD is caused by mutations in C9ORF72, MAPT, or GRN genes¹²¹² The majority of genetic FTD is caused by mutations in C9ORF72, MAPT, or GRN genes
About 10-20% of all FTD cases are genetic. While pathogenic mutations in MAPT cause familial FTD with autosomal dominant inheritance, the common H1 haplotype also contributes to sporadic FTD risk, particularly the H1c subclade¹³¹³ the common H1 haplotype also contributes to sporadic FTD risk, particularly the H1c subclade
A 2024 GWAS of 4,685 sporadic FTD cases found genome-wide significant association at the MAPT locus (p = 2.5×10⁻¹²).

Mechanism and Splicing

Studies using whole-locus genomic MAPT expression vectors demonstrate that intronic variants like rs1800547 and rs17651213 regulate haplotype-specific splicing of exon 3¹⁴¹⁴ Studies using whole-locus genomic MAPT expression vectors demonstrate that intronic variants like rs1800547 and rs17651213 regulate haplotype-specific splicing of exon 3
The splicing factors hnRNP F and hnRNP Q mediate this haplotype-specific regulation. The H2 haplotype is associated with lower total MAPT expression and altered isoform ratios compared to H1¹⁵¹⁵ The H2 haplotype is associated with lower total MAPT expression and altered isoform ratios compared to H1
This may explain the differential tauopathy risk profiles. Specifically, H1 appears to favor production of 4R tau isoforms, which may explain its association with 4R tauopathies like PSP and CBD.

Aging and Bradykinesia

Even in neurologically healthy older adults, the H2 haplotype is associated with age-related motor impairment, particularly bradykinesia (slowness of movement)¹⁶¹⁶ the H2 haplotype is associated with age-related motor impairment, particularly bradykinesia (slowness of movement)
This suggests MAPT variants influence aging-related functional decline independent of clinical disease. The mechanism appears distinct from classical Parkinson's disease and may involve cortico-nigro-striatal pathways different from those typically affected in PD.

Interactions

The H1/H2 haplotype interacts with other genetic risk factors. In Huntington's disease (a secondary tauopathy), H2 carriers show more rapid cognitive decline compared to H1 carriers¹⁷¹⁷ H2 carriers show more rapid cognitive decline compared to H1 carriers
This suggests tau pathology contributes to HD progression. In APOE ε4 non-carriers, the MAPT H1 haplotype becomes a more prominent risk factor for Alzheimer's disease¹⁸¹⁸ In APOE ε4 non-carriers, the MAPT H1 haplotype becomes a more prominent risk factor for Alzheimer's disease
This suggests genetic interactions between the two major AD risk loci.

The relationship between MAPT haplotypes and alpha-synuclein pathology (the hallmark of Parkinson's disease) remains incompletely understood, though interaction analyses have not found evidence of epistatic effects between SNCA and MAPT loci¹⁹¹⁹ interaction analyses have not found evidence of epistatic effects between SNCA and MAPT loci
The two risk factors appear to act independently.

The insulin receptor is the master switch for glucose metabolism. When insulin binds to its extracellular alpha subunit, it triggers a conformational change that activates the intracellular beta subunit's tyrosine kinase domain — initiating a cascade that opens glucose transporters, suppresses glucose production, and directs energy storage. Variants in the tyrosine kinase domain, even synonymous ones that don't change the amino acid sequence, can subtly alter how this switch operates.

rs1799817 (His1085His) is a C→T transition on the coding strand of exon 17, which encodes part of the catalytic kinase domain. On the plus strand used by genome files, the alleles are G (reference) and A (alternate). Despite producing no amino acid change, this variant sits adjacent to the ATP-binding site critical for receptor autophosphorylation — the event that initiates insulin signaling.

The Mechanism

Synonymous variants in coding regions were long assumed to be functionally inert. More recently, evidence has accumulated that so-called silent polymorphisms¹¹ silent polymorphisms
Silent variants can influence mRNA secondary structure, codon usage, and exon splicing enhancer sequences — all of which alter the efficiency of protein translation and the final level of functional receptor at the cell surface. can perturb mRNA processing, codon translation efficiency, or splicing enhancer elements²² splicing enhancer elements
Exonic splicing enhancers (ESEs) are short consensus sequences within exons that recruit splicing factors. A synonymous SNP that disrupts an ESE can cause exon skipping or intron retention, potentially altering the reading frame or domain composition of the final protein. within exon 17.

The H1085 position is located near the ATP-binding cleft of the INSR tyrosine kinase domain. While the substitution of one histidine codon for another (CAC→CAT) does not change the amino acid, it may alter local mRNA secondary structure and translational speed, potentially affecting the co-translational folding of the kinase domain. The downstream consequence — proposed in multiple studies — is increased serine phosphorylation of the receptor, a modification that competitively inhibits tyrosine autophosphorylation and blunts post-receptor insulin signaling.

The Evidence

The most consistent finding across studies is an association between the A allele (coding-strand T; rs1799817) and PCOS risk, particularly in lean women.

A 2020 Saudi Arabian case-control study³³ 2020 Saudi Arabian case-control study
Alnaaim et al. RS1799817 in INSR associates with susceptibility to polycystic ovary syndrome. Int J Clin Pract. 2020. PMID:33033446 (126 PCOS cases, 118 controls) found the T allele significantly enriched in PCOS women (allele frequency 0.306 vs. 0.174 in controls, p<0.001). The relative risk was 2.82 in heterozygotes, with the association most pronounced in lean PCOS women who had elevated HOMA-IR.

An Indian cohort study (Vasan et al. 2020⁴⁴ Vasan et al. 2020
Vasan et al. Association of GWAS identified INSR variants with PCOS in Indian women. Int J Biol Macromol. 2020. PMID:31837364) showed OR 11.8 (95% CI 6.3–22.3) for PCOS among T allele carriers (n=240), with significantly higher serum insulin and testosterone levels in the risk-allele group.

Earlier work by Mukherjee et al. 2009⁵⁵ Mukherjee et al. 2009
Mukherjee et al. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with PCOS. Eur J Endocrinol. 2009. PMID:19211708 showed that C/T heterozygotes in lean PCOS women had significantly higher HOMA-IR and free androgen index compared to C/C homozygotes — the key functional connection between the INSR variant and the PCOS phenotype.

However, the picture is not uniform. A 2021 meta-analysis⁶⁶ 2021 meta-analysis
Cao et al. Replication study and meta-analysis of selected genetic variants and polycystic ovary syndrome susceptibility in Asian population. J Assist Reprod Genet. 2021. PMID:34403018 pooling 3,635 participants across 15 Asian studies found no statistically significant association in the overall pooled analysis — though individual studies in Korean and Chinese subsets showed significant effects. This heterogeneity likely reflects differences in PCOS diagnostic criteria, BMI stratification, and population structure across studies.

Practical Actions

The primary clinical implication of this variant is for women in whom standard PCOS screening may be warranted. The variant is associated most strongly with insulin resistance in lean women — a presentation of PCOS that is frequently missed because insulin resistance is often assumed to require obesity.

Fasting insulin and HOMA-IR⁷⁷ HOMA-IR
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) = fasting insulin (µIU/mL) × fasting glucose (mmol/L) ÷ 22.5. Values above 2.0-2.5 are typically considered indicative of insulin resistance. monitoring provides a non-invasive window into whether receptor signaling is impaired, regardless of body weight.

Interactions

rs1799817 is in moderate linkage disequilibrium with rs2059807, another INSR variant that tags the same GWAS signal identified in Han Chinese populations. Carrying both risk alleles compounds the signal at the INSR locus. The INSR locus interacts with the THADA locus (rs13429458) in PCOS GWAS — these represent independent pathways (insulin receptor signaling vs. Ca²⁺ channel/thyroid adenoma-associated gene), and women with risk variants at both loci show additive increases in metabolic syndrome prevalence.

Endothelial nitric oxide synthase (eNOS), encoded by the NOS3 gene, produces nitric oxide (NO) in the lining of blood vessels. Nitric oxide is one of the most important molecules in cardiovascular biology - it relaxes blood vessel walls, prevents blood clots from forming, and reduces inflammation in the arterial lining.

The Mechanism

The Glu298Asp ¹¹ Glutamic acid to aspartic acid at position 298 variant (rs1799983) replaces glutamic acid with aspartic acid at position 298 of the eNOS protein. The T allele (Asp) makes the enzyme more susceptible to cleavage and degradation, reducing the steady-state amount of functional eNOS in endothelial cells. Less enzyme means less nitric oxide production, which can lead to stiffer blood vessels, higher blood pressure, and increased oxidative stress.

The Uncoupling Problem

When eNOS is impaired, it can become "uncoupled" ²² Uncoupled eNOS produces harmful superoxide instead of beneficial nitric oxide - instead of producing beneficial nitric oxide, it generates superoxide, a harmful reactive oxygen species. This switches the enzyme from being protective to actively damaging. Adequate levels of BH4 ³³ BH4 is an essential cofactor that keeps eNOS in its coupled, NO-producing state (tetrahydrobiopterin), a critical cofactor, help prevent uncoupling.

The Evidence

A large meta-analysis⁴⁴ large meta-analysis
Casas JP et al. Endothelial Nitric Oxide Synthase Genotype and Ischemic Heart Disease. Circulation, 2004 of 26 studies involving 23,028 individuals confirmed that the TT genotype is associated with increased risk of ischemic heart disease (OR 1.31, 95% CI 1.13-1.51). A subsequent meta-analysis of 60 studies⁵⁵ meta-analysis of 60 studies
Association between eNOS rs1799983 polymorphism and hypertension. BMC Cardiovasc Disord, 2021 involving 14,185 hypertension cases and 13,407 controls found significant associations under all genetic models (TT vs GG: OR 1.80, 95% CI 1.41-2.31). The effect is more pronounced when combined with the NOS3 promoter variant (rs2070744) and lifestyle factors like smoking, sedentary behavior, and poor diet.

Practical Implications

Dietary nitrates from beets, spinach, and arugula can boost NO production through an alternative pathway ⁶⁶ Oral bacteria convert dietary nitrate to nitrite, which is then reduced to NO in the acidic stomach environment that bypasses eNOS entirely. Regular aerobic exercise is one of the most potent stimulators of eNOS activity and NO production. Vitamin C and other antioxidants help prevent eNOS uncoupling by supporting BH4 recycling.

CYP2E1 is the enzyme your liver uses to metabolize ethanol, acetaminophen, industrial solvents, and dozens of environmental procarcinogens. It is also one of the most prolific generators of reactive oxygen species in the body — every time CYP2E1 processes a substrate, it produces free radicals as a byproduct. The *5B variant (rs2031920) sits 2 kb upstream of the gene in the promoter region, where it alters the transcriptional response to ethanol, ketones, and fasting. Carriers of the T allele have a more inducible CYP2E1 — their enzyme ramps up higher in response to triggers, generating more oxidative stress with each exposure. The variant is rare in Europeans (~3%) and Africans (<1%) but occurs in roughly 1 in 5 East Asians, making it a particularly important pharmacogenomic consideration in those populations.

The Mechanism

The -1053C>T substitution (the *5B RsaI polymorphism) falls within the 5' upstream regulatory region¹¹ upstream regulatory region
non-coding region upstream of the gene that controls how strongly and how often the gene is transcribed of CYP2E1. The T allele creates altered binding affinity for transcription factors that respond to ethanol, starvation, and insulin suppression. The functional result is a higher peak expression level after exposure: when an enzyme surge occurs, the T allele carrier's CYP2E1 climbs higher and stays elevated longer. Because CYP2E1 is an inherently leaky enzyme²² leaky enzyme
CYP2E1 has an unusually high rate of uncoupled catalysis — electrons escape the reaction and reduce oxygen to superoxide rather than finishing the productive catalytic cycle with a high rate of reactive oxygen species³³ reactive oxygen species
ROS: unstable oxygen-containing molecules that damage proteins, lipids, and DNA generation, this induction translates directly into elevated oxidative stress in the liver and other tissues.

The Evidence

Colorectal cancer: A 2013 meta-analysis of 17 studies comprising 17,082 individuals⁴⁴ 2013 meta-analysis of 17 studies comprising 17,082 individuals
Peng H et al. Associations of CYP2E1 rs2031920 and rs3813867 polymorphisms with colorectal cancer risk. Tumour Biology, 2013 found the c2 (T) allele associated with a significant increase in colorectal cancer risk (OR 1.19, 95% CI 1.03–1.37). This was confirmed by a 2022 meta-analysis of 23,598 subjects across 18 studies⁵⁵ 2022 meta-analysis of 23,598 subjects across 18 studies
Sharzehan MA et al. Association between CYP2E1 polymorphisms and colorectal cancer risk. Scientific Reports, 2022, which found an even stronger association in the homozygous model (OR 1.50, 95% CI 1.18–1.90).

Alcoholic liver disease: A case-control study in Indian patients⁶⁶ case-control study in Indian patients
Khan AJ et al. Polymorphism in CYP2E1 and susceptibility to alcoholic liver cirrhosis. Mutation Research, 2009 found the *5B T-A-T haplotype associated with a 4.3-fold increased risk of alcoholic cirrhosis (OR 4.3, 95% CI 1.5–12.4) compared to non-alcoholic controls, rising to 5.4-fold against non-alcoholic cirrhosis patients. A Mexican study found the c2 allele twice as common in cirrhosis patients as in controls (19.5% vs 10.6%)⁷⁷ c2 allele twice as common in cirrhosis patients as in controls (19.5% vs 10.6%)
García-Bañuelos J et al. Genetic polymorphisms of alcohol-metabolizing enzymes in western Mexicans. Alcohol Clin Exp Res, 2012, with c2 carriers also showing worse liver function parameters.

Lung cancer and smoking interactions: A Japanese case-control study of 841 participants⁸⁸ case-control study of 841 participants
Kakino K et al. CYP2E1 rs2031920, COMT rs4680 and lung cancer in Japanese population. Asian Pac J Cancer Prev, 2016 found that the CC genotype (no T allele) in heavy smokers conferred OR 3.57 (95% CI 2.26–5.63) for lung cancer compared to non-smoking T-allele carriers — a complex interaction suggesting that the T allele's role in carcinogen activation depends on exposure context.

Benzene toxicity: The CYP2E1 rapid metabolizer phenotype (which the c2 allele promotes) combined with NQO1 TT genotype (rs1800566) was found to produce 8- to 21-fold increased benzene poisoning risk⁹⁹ 8- to 21-fold increased benzene poisoning risk
Wan J et al. Genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, GSTT1 and benzene poisoning. Environ Health Perspect, 2002.

Practical Actions

The *5B variant matters most when CYP2E1 is actively engaged — during alcohol consumption, acetaminophen use, fasting, and occupational chemical exposures. The T allele's higher inducibility means that the same exposure produces greater oxidative stress in a T-carrier's liver than in a CC individual. The most directly modifiable risk factors are acetaminophen dose and alcohol consumption. Antioxidant support (particularly NAC, which replenishes glutathione depleted by CYP2E1-generated ROS) is a targeted intervention specifically relevant to this variant.

Interactions

The most clinically important interaction is with rs1800566 (NQO1 C609T). NQO1 normally detoxifies CYP2E1-generated quinones and reactive metabolites; when both CYP2E1 is overactive (rs2031920 T allele) and NQO1 is absent or reduced (rs1800566 TT), the combined risk for benzene toxicity and related haematotoxicity is multiplicative rather than additive, reaching 8- to 21-fold increased risk in occupationally exposed workers. The companion promoter SNP rs3813867 (CYP2E1 *6, DraI polymorphism) tags the same haplotype block and is often studied together with rs2031920; however, multiple meta-analyses find that rs3813867 alone has no significant effect on cancer risk whereas rs2031920 does.

HNF4A¹¹ HNF4A
Hepatocyte Nuclear Factor 4 Alpha — a nuclear receptor transcription factor essential for pancreatic beta-cell identity, hepatic lipid metabolism, and glucose homeostasis is one of the most important metabolic transcription factors in the body. Unlike many diabetes genes that act through a single pathway, HNF4A controls the expression of dozens of downstream targets including GLUT2 (glucose transporter), glucokinase, mitochondrial enzymes, and other transcription factors such as HNF1A. Loss-of-function mutations in HNF4A cause MODY1²² MODY1
Maturity-Onset Diabetes of the Young type 1 — a monogenic, autosomal dominant diabetes caused by HNF4A haploinsufficiency in beta cells; characterised by early-onset non-insulin-dependent diabetes in lean individuals.

rs2144908 sits in an intron of HNF4A on the GRCh38 plus strand (chr20:44,357,077) and is one of four variants — along with rs4810424, rs1884613, and rs1884614 — that define the common HNF4A P2 promoter haplotype block. This block tags regulatory variation in the P2 promoter, the alternative upstream promoter that drives HNF4A expression specifically in pancreatic beta cells (and, to a lesser extent, fetal liver).

The Mechanism

The HNF4A gene has two functional promoters. The P1 promoter is active in adult liver and drives the HNF4A1–6 isoform family. The P2 promoter is active in pancreatic beta cells and drives the HNF4A7–12 family — also known as the "fetal" isoforms — which persist into adulthood in the pancreas. The P2 promoter is controlled partly by HNF1A, creating a transcriptional feedback circuit: HNF4A (P2 isoform) → HNF1A → HNF4A, which is disrupted by variants in either gene, as confirmed by Kind et al. 2024 (Diabetes)³³ Kind et al. 2024 (Diabetes)
HNF-1A mediates HNF4A P2 promoter regulation; P2-linked mutations impair glucose-stimulated insulin secretion in beta cells. Diabetes, 2024.

The A allele at rs2144908 tags a P2 haplotype associated with mildly reduced P2 promoter activity in beta cells — or altered responsiveness of the promoter to transcriptional activators. The consequence is reduced HNF4A protein in beta cells, which impairs the cell's ability to ramp up insulin secretion in response to rising blood glucose. In the adult liver, the same P2 isoform becomes aberrantly re-expressed in type 2 diabetes⁴⁴ aberrantly re-expressed in type 2 diabetes
Chronically elevated P2 isoform in diabetic liver promotes excess hepatic glucose production through a glucagon→TET3→FOXA2→P2 demethylation axis, compounding hyperglycemia on top of impaired insulin secretion. The A allele at rs2144908 thus implicates both pancreatic and hepatic arms of glucose dysregulation.

The Evidence

The HNF4A P2 haplotype was originally identified in Finnish and Ashkenazi populations in 2004, and rs2144908 was one of the four SNPs used by Weedon et al. 2004⁵⁵ Weedon et al. 2004
Common variants of the hepatocyte nuclear factor-4alpha P2 promoter are associated with type 2 diabetes in the U.K. population. Diabetes, 2004 to tag the risk haplotype in 5,256 UK subjects, where the risk haplotype carried an OR of 1.15 (95% CI 1.02–1.33, P=0.02). A 2007 Norwegian population study and meta-analysis by Johansson et al.⁶⁶ Johansson et al.
Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects indicate HNF4A P2 region variants are associated with type 2 diabetes in Scandinavians. Diabetes, 2007 reported rs2144908 itself with OR 1.21 (95% CI 1.05–1.38) in the Norwegian cohort, and a Scandinavian-restricted meta-analysis OR of 1.14 (1.06–1.23, P=0.0004) for the lead P2 tag SNP rs1884613.

In North Indian subjects, Chavali et al. 2011⁷⁷ Chavali et al. 2011
Association of variants in genes involved in pancreatic beta-cell development and function with type 2 diabetes in North Indians. J Hum Genet, 2011 found rs2144908 significantly associated with T2D (OR 1.37, 95% CI 1.20–1.57, P=6.0×10⁻⁶) in 2,025 subjects, with the effect notably stronger in normal-weight individuals — consistent with a primary beta-cell deficiency mechanism rather than an obesity-driven insulin resistance pathway.

The A allele is the minor allele in Europeans (~17%) and Africans (~11%), but has much higher frequency in East Asians (~46%) and South Asians (~27%). Effect sizes have been inconsistent across populations, partly because the causal functional variant within the P2 haplotype block has not been definitively identified, and the LD pattern between rs2144908 and the true causal variant differs by ancestry.

Practical Actions

The A allele at rs2144908 modestly impairs glucose-stimulated insulin secretion through reduced HNF4A activity in beta cells. For heterozygous AG carriers (the most common at-risk genotype), the risk elevation per allele is modest (OR ~1.15–1.21), equivalent to roughly a 15–20% increase in relative risk for type 2 diabetes. This is not alarming in isolation, but becomes clinically meaningful when combined with additional T2D risk factors (family history, excess weight, sedentary lifestyle, other T2D-associated variants). Periodic monitoring of fasting glucose and HbA1c is the core intervention, since early detection of prediabetes enables lifestyle changes that can prevent progression. Reducing postprandial glucose spikes through low-glycemic- index carbohydrate choices directly compensates for reduced beta-cell secretory reserve.

For homozygous AA carriers, who carry both copies of the risk haplotype, an oral glucose tolerance test (OGTT) provides more sensitive detection of beta-cell secretory impairment than fasting glucose alone, since the OGTT specifically challenges the glucose-stimulated insulin secretion pathway disrupted by this locus.

Interactions

rs2144908 is in strong linkage disequilibrium (D' > 0.97, r² > 0.90) with rs4810424, rs1884613, rs1884614, and rs6031552 — all of which tag the same P2 haplotype block. These variants do not represent independent risk signals; they capture the same underlying haplotype. Carrying risk alleles at multiple P2 block SNPs does not add cumulative independent risk beyond the haplotype itself.

Functionally, HNF4A and KCNJ11 (rs5219, Kir6.2 E23K) interact: HNF4A is a known transcriptional regulator of the KCNJ11 gene. Qi et al. 2007⁸⁸ Qi et al. 2007
Gene-gene interactions between HNF4A and KCNJ11 in predicting type 2 diabetes in women. Diabet Med, 2007 found significant interactions between HNF4A rs2144908 and KCNJ11 E23K in predicting T2D risk in women (P=0.017), with combined minor allele carriage substantially elevating risk above either variant alone. TCF7L2 rs7903146 (Wnt/incretin pathway) impairs a third independent beta-cell secretory mechanism; carriers of both HNF4A P2 and TCF7L2 risk alleles face compounded beta-cell dysfunction warranting earlier glucose monitoring.

Adiponectin is one of the most important hormones your body makes — and unlike most hormones, it is produced exclusively by fat cells. This may seem counterintuitive: how can fat tissue secrete a hormone that protects against the very diseases associated with excess fat? The answer lies in adiponectin's remarkable properties: it simultaneously suppresses hepatic glucose production, enhances skeletal muscle fatty acid oxidation, and reduces vascular inflammation. People with high adiponectin levels have lower rates of type 2 diabetes, less coronary artery disease, and better insulin sensitivity regardless of their body weight. The rs2241767 variant is one of several intronic polymorphisms in the ADIPOQ gene that quietly alters how much of this protective hormone your fat cells release.

rs2241767 sits in intron 2 of ADIPOQ¹¹ intron 2 of ADIPOQ
The second non-coding segment of the adiponectin gene, 135 nucleotides downstream of the second coding exon, at GRCh38 position chr3:186853407, where the A-to-G substitution on the plus strand (c.214+135A>G) affects regulatory sequences that govern adiponectin transcription or mRNA processing. The G allele has a global frequency of roughly 11%, but with striking population variation: it reaches 29% in East Asian populations while falling to just 4% in African populations, making ancestry-aware interpretation important.

The Mechanism

Intronic variants like rs2241767 can influence gene expression through multiple mechanisms: altered binding of transcription factors to intronic enhancer elements, changes in pre-mRNA splicing efficiency²² pre-mRNA splicing efficiency
The process by which introns are removed from precursor RNA — variants near splice regulatory sequences can subtly shift splice site usage even if they're not at the consensus splice site itself, or effects on local chromatin accessibility. The rs2241767 G allele lies in a region of ADIPOQ intron 2 that is in partial linkage disequilibrium³³ linkage disequilibrium
The tendency for nearby genetic variants to be inherited together, meaning rs2241767 may tag other functional variants in the same haplotype block with the exon 2 synonymous variant rs2241766 (T45G), which is separately associated with reduced mRNA stability and lower adiponectin secretion.

The net result of carrying the G allele at rs2241767 is measurably lower circulating adiponectin. Because adiponectin acts as a brake on hepatic glucose output and a stimulant of skeletal muscle AMPK⁴⁴ AMPK
AMP-activated protein kinase — a master regulator of cellular energy status that is directly activated by adiponectin and mimics some of the metabolic effects of exercise and calorie restriction activation, reduced adiponectin translates to greater insulin resistance under conditions of metabolic stress — particularly in individuals who are already carrying excess adipose tissue.

The Evidence

The association between rs2241767 and metabolic outcomes has been replicated across diverse populations. In a Chinese Han case-control study⁵⁵ Chinese Han case-control study
1,105 type 2 diabetes patients and 1,107 controls by Du et al. (2011), AG/GG carriers showed significantly lower serum adiponectin levels than AA homozygotes (P=0.044), and the AG genotype was associated with a 32% higher risk of type 2 diabetes specifically in obese participants (adjusted OR 1.32, 95% CI 1.03–1.69). The interaction with obesity is biologically coherent: when adipose tissue is already inflamed and dysfunctional, impaired adiponectin secretion from the G allele removes a critical compensatory mechanism.

Cardiovascular findings from the MESA study⁶⁶ MESA study
Multi-Ethnic Study of Atherosclerosis, a large prospective cohort of 6,814 participants free of clinical cardiovascular disease at enrollment by Wassel et al. (2011) showed that in African American participants, AG/GG carriers had a 36% higher prevalence of coronary artery calcification⁷⁷ coronary artery calcification
Calcium deposits in coronary artery walls detected by CT scan, a direct measure of subclinical atherosclerosis and a strong predictor of future heart attack risk (P=0.0001) and significantly greater carotid intima-media thickness⁸⁸ carotid intima-media thickness
An ultrasound measure of artery wall thickness in the carotid arteries, reflecting cumulative atherosclerotic burden (P=0.0043) compared to AA carriers. These findings were specific to African Americans and Hispanics — the G allele is sufficiently rare in those populations that even modest effects remain detectable, while in European and Chinese populations the signal is diluted by other adiponectin-pathway variants at higher frequency.

In a South Indian population study⁹⁹ South Indian population study
1,100 type 2 diabetic patients and 1,100 normoglycemic controls from the Chennai Urban Rural Epidemiology Study by Ramya et al. (2013), rs2241767 showed an independent association with central obesity — the abdominal fat deposition pattern most strongly linked to metabolic syndrome — distinct from its effects on diabetes risk per se. In Mexican American families from the San Antonio Family Heart Study, rs2241767 was significantly associated with skin fold thickness¹⁰¹⁰ rs2241767 was significantly associated with skin fold thickness
A surrogate for subcutaneous adiposity and fat distribution (P=0.013) in the context of insulin resistance syndrome phenotypes, suggesting the variant's effects on fat distribution may be separable from glycemic effects.

The broader genetic architecture of the ADIPOQ locus — established as the dominant single genetic determinant of plasma adiponectin levels¹¹¹¹ established as the dominant single genetic determinant of plasma adiponectin levels
Explaining approximately 6.7% of phenotypic variance in Europeans across a GWAS of 18,454 subjects — means rs2241767's effects are best understood as part of a haplotype. The variant is in partial LD with rs2241766, rs1501299, and rs266729, and the combination of risk alleles across the locus has a larger impact on adiponectin than any single variant alone.

Practical Actions

Carriers of the G allele cannot directly modify the upstream genetic impairment in adiponectin secretion, but several nutrient and lifestyle factors can raise circulating adiponectin levels independent of genotype. Long-chain omega-3 fatty acids (EPA and DHA) are the best-supported dietary upregulators of adiponectin expression in adipose tissue — multiple randomized trials show that 2–4 g EPA/DHA per day raises adiponectin by 10–25%, with the effect strongest in people with low baseline adiponectin. Magnesium deficiency independently suppresses adiponectin secretion and worsens insulin resistance through AMPK-dependent pathways; AG/GG carriers who are also magnesium-insufficient compound both deficiencies.

Because the G allele's effect on T2D risk is specifically amplified in overweight individuals, the practical implication for G carriers is that the genotype-environment interaction is the key risk driver. Keeping adipose tissue lean and metabolically healthy eliminates most of the excess risk — but the mechanism is different from the generic "maintain healthy weight" advice: the G allele increases the metabolic penalty per unit of excess adiposity because each kilogram of extra fat tissue secretes less adiponectin in G carriers than in AA carriers.

Monitoring fasting insulin and adiponectin levels directly provides useful biomarker feedback for G carriers — these tests quantify the actual metabolic consequence of the variant and can motivate and track intervention effectiveness before glucose tolerance deteriorates.

Interactions

rs2241767 is in partial LD with two other ADIPOQ variants already in the GeneOps database: rs2241766 (T45G, exon 2 synonymous) and rs1501299 (+276G>T, intron 2). Individuals carrying risk alleles at all three variants — which tend to cluster on the same haplotype — show substantially greater reduction in adiponectin levels than any single variant predicts. The combined low-adiponectin haplotype interacts particularly strongly with excess adiposity and with rs266729 (the -11365C>G promoter variant associated with reduced ADIPOQ transcription). The compounding of these effects within the ADIPOQ locus is the basis for proposing interaction actions across these variants.

Your body has a master switch that controls how much fat gets pulled out of your bloodstream after a meal. That switch is ANGPTL4¹¹ ANGPTL4
Angiopoietin-like protein 4 — a secreted protein that acts as a context-sensitive brake on fat-clearing enzymes, and this variant in its gene is linked to how effectively it operates. People with the A allele at rs2278236 tend to carry higher HDL cholesterol and face a measurably lower risk of cardiovascular events.

The Mechanism

ANGPTL4 works by inhibiting lipoprotein lipase (LPL)²² lipoprotein lipase (LPL)
LPL is the enzyme that breaks down triglycerides in VLDL and chylomicrons, releasing fatty acids for uptake into muscle and adipose tissue. When ANGPTL4 is highly active, it clamps down on LPL, meaning triglycerides accumulate in the blood rather than being cleared efficiently. When ANGPTL4 activity is lower — as appears to be tagged by the A allele at rs2278236 — LPL can work more freely, clearing triglycerides from circulation and generating HDL particles as a byproduct of that lipolytic process.

The variant sits within an intron of ANGPTL4 and does not change the protein sequence directly. It is most likely a regulatory tag — either altering expression levels or in linkage disequilibrium with a functional variant elsewhere in the gene that modulates ANGPTL4 output.

The Evidence

A prospective cohort study of 983 coronary patients³³ 983 coronary patients
Muendlein et al. Angiopoietin-like protein 4 significantly predicts future cardiovascular events in coronary patients. Atherosclerosis, 2014 found that rs2278236 significantly predicted future cardiovascular events independently of conventional risk factors. Carrying the A allele was associated with a 24% lower event rate (adjusted HR 0.76, 95% CI 0.61–0.94, p=0.012). Plasma ANGPTL4 levels were higher in patients with metabolic syndrome (26.0 vs 22.2 ng/ml, p=0.008), supporting the connection between ANGPTL4 activity and cardiometabolic risk.

GWAS data in the EBI GWAS Catalog show rs2278236-A is associated with increased HDL cholesterol at genome-wide significance (p=1×10⁻¹⁶) and also with increased phosphatidylcholine, total cholines, and phosphoglycerides in lipoprotein particles (p=2×10⁻¹⁸ to 3×10⁻¹⁷), consistent with a shift toward a more favorable lipoprotein particle profile.

Diet-gene interaction is also documented: a randomized controlled trial⁴⁴ randomized controlled trial
Hannon et al. SNPs Related to Lipoprotein Metabolism Are Associated with Blood Lipid Changes following Regular Avocado Intake. J Nutr, 2020 of 115 adults found that ANGPTL4 rs2278236 genotype modified total cholesterol responses to regular avocado intake (interaction p=0.02), suggesting the variant shapes how dietary fat quality translates into lipid outcomes.

Notably, a study in 629 white adults at risk for type 2 diabetes found no association⁵⁵ found no association
Staiger et al. Genetic variation within ANGPTL4 is not associated with metabolic traits. Metabolism, 2008 between rs2278236 and fasting triglycerides, insulin sensitivity, or BMI in cross-sectional analysis, suggesting the variant's benefit may be more apparent under metabolic challenge (high dietary fat load, cardiovascular disease context) than at rest.

Practical Actions

For GG carriers — the group with lowest HDL-raising allele count — the actionable lever is dietary fat quality and omega-3 intake. Because ANGPTL4 activity is sensitive to fatty acid composition, shifting from saturated fats (which upregulate ANGPTL4) to unsaturated fats and EPA/DHA can partly compensate for less favorable ANGPTL4 regulation. Routine fasting lipid panels including HDL, triglycerides, and non-HDL cholesterol will track whether these changes are working.

AA carriers still benefit from similar strategies but start from a more favorable HDL baseline.

Interactions

ANGPTL4 operates within a three-protein system alongside ANGPTL3 and ANGPTL8 that coordinates tissue-specific LPL regulation. The variant rs4076317 (another ANGPTL4 tag SNP) has been studied in the same coronary patient cohort and may compound lipid effects. ANGPTL3 variants (e.g., rs2131925) represent a related LPL-inhibition pathway; combined ANGPTL3 + ANGPTL4 effects on triglycerides may be additive.

Matrix metalloproteinase-2 (MMP-2), also called gelatinase A, is the body's primary enzyme for dissolving type IV collagen — the scaffolding that forms basement membranes throughout virtually every tissue. When fat cells expand, when capillaries branch, when wounds heal, MMP-2 is the molecular digger clearing the way by breaking down this dense collagen framework. MMP-2 is constitutively expressed and tightly regulated by a complex involving MT1-MMP (MMP14) and TIMP-2¹¹ MMP-2 is constitutively expressed and tightly regulated by a complex involving MT1-MMP (MMP14) and TIMP-2
Unlike most MMPs which require inflammatory induction, MMP-2 is always present in tissue at baseline, activated or inhibited depending on the local balance of its cofactors. In adipose tissue specifically, MMP-2 activity is essential for the ECM remodeling that accommodates fat-cell expansion; without it, adipocyte growth is constrained by a rigid collagen cage.

The rs243865 variant, a C→T transition at position –1306 of the MMP2 promoter, sits directly within an Sp1-binding site (CCACC box)²² Sp1-binding site (CCACC box)
Sp1 is a transcription factor that binds CCACC sequences in gene promoters to drive constitutive gene expression. The T allele destroys this binding site, reducing MMP-2 promoter activity by approximately 50% compared to the C allele. The result: TT carriers produce significantly less MMP-2 enzyme than CC carriers; CT heterozygotes are intermediate.

The Mechanism

This is a classic regulatory variant³³ regulatory variant
A variant that affects how much of a gene is produced, rather than altering the protein's structure or function. When the C allele is present, Sp1 binds normally and drives full MMP-2 transcription. The T allele disrupts this binding, resulting in lower baseline MMP-2 expression. Since MMP-2 protein structure is unchanged, whatever enzyme is produced by T allele carriers is fully functional — there is simply less of it.

In adipose tissue, the consequence is a shift in the balance between ECM rigidity and remodeling capacity. Low MMP-2 expression means slower breakdown of basement membrane collagen IV, reduced capillary sprouting, and impaired accommodation of expanding adipocytes. Over time, chronic low MMP-2 activity promotes ECM stiffness and fibrosis — hallmarks of lipedema pathology where progressive interstitial collagen accumulation and connective tissue thickening accompany uncontrolled lower-body adipose expansion. Lipedema adipose tissue shows significantly altered MMP expression including decreased MMP2, MMP9, and MMP11⁴⁴ Lipedema adipose tissue shows significantly altered MMP expression including decreased MMP2, MMP9, and MMP11
This parallels the reduced ECM remodeling capacity seen genetically in high-C-allele carriers.

Conversely, CC carriers with high MMP-2 production have more active ECM remodeling — providing more flexible tissue accommodation for fat cell expansion, but also potentially contributing to structural instability in other contexts (vessel walls, basement membranes in stressed tissues).

The Evidence

The functional consequence of this polymorphism was established in two landmark studies. Price et al. 2002⁵⁵ Price et al. 2002
781 lung cancer cases and 852 controls in a Chinese population; p < 0.001 for genotype association showed that CC genotype carried a 2.2-fold increased risk for lung cancer (OR 2.18, 95% CI 1.70–2.79), with the effect amplified 10-fold in heavy smokers. Ye et al. 2003⁶⁶ Ye et al. 2003
274 gastric cardia adenocarcinoma cases and 426 controls replicated the finding with an even larger effect (OR 3.36, 95% CI 2.34–4.97 for CC vs CT/TT). Both studies confirmed the functional mechanism: T allele disrupts the Sp1 site and reduces promoter activity by ~50%.

A 2015 meta-analysis⁷⁷ 2015 meta-analysis
29 case-control studies, 8,590 cancer cases and 9,601 controls across multiple cancer types confirmed the direction: CT genotype was significantly protective compared to CC (OR 0.758, 95% CI 0.637–0.902), and the dominant model (CT+TT vs CC) also showed protective effect (OR 0.816, 95% CI 0.678–0.982). The TT homozygous state did not show additional protection over CT, suggesting the primary benefit is from having at least one T allele to reduce Sp1 binding.

For body composition, Chang et al. 2011⁸⁸ Chang et al. 2011
546 New Zealand children aged 7 years; part of the CHDS cohort found that the C allele of rs243865 was associated with higher percentage body fat (estimate 1.40, 95% CI 0.16–2.64, p = 0.027), though this was attenuated after covariate adjustment (p = 0.055). The broader MMP-2 promoter haplotype including rs243865 remained significantly associated with body fat percentage after full adjustment (p = 0.040), indicating the C allele's effect on adipose ECM remodeling has measurable phenotypic consequences even in childhood.

The cardiovascular picture is more nuanced. A dedicated meta-analysis on coronary artery disease⁹⁹ meta-analysis on coronary artery disease
2,118 samples found no significant association between -1306 C/T and CAD risk overall (OR 0.93, 95% CI 0.78–1.10). However, a 2025 cross-sectional study in resistant hypertension¹⁰¹⁰ 2025 cross-sectional study in resistant hypertension
78 patients with treatment-resistant hypertension; small sample but detailed phenotyping found that T allele carriers had significantly lower ejection fraction (OR 8.1, 95% CI 1.3–51.4) and higher carotid artery stenosis prevalence (OR 4.5, 95% CI 1.1–20.1). In this high-cardiovascular-risk setting, lower MMP-2 expression may impair adaptive vascular remodeling.

Evidence level for this SNP is moderate: the functional mechanism is well-established and replicated across multiple systems, but most associations are from case-control studies with population-specific effects, and there are no clinical practice guidelines.

Practical Implications

For CC carriers (the majority), high MMP-2 production supports active ECM remodeling — helpful for normal adipose expansion, angiogenesis, and tissue adaptation, but potentially problematic when chronic inflammation drives sustained matrix degradation. Supporting connective tissue integrity through adequate vitamin C (collagen synthesis), omega-3 fatty acids (anti-inflammatory reduction of MMP overactivation), and protein intake to maintain the structural proteins that MMP-2 degrades becomes especially relevant.

For TT carriers, reduced MMP-2 expression means the ECM is less remodeled — which reduces cancer risk through slower basement membrane breakdown and tumor invasion, but may limit adipose tissue adaptability and reduce vascular remodeling capacity under cardiovascular stress. The reduced cancer risk from the T allele should not be confused with protection from cardiovascular fibrosis.

For the lipedema context specifically, both extremes create risk through different mechanisms: excess MMP-2 (CC) may drive uncontrolled remodeling and capillary fragility, while deficient MMP-2 (TT) impairs the orderly matrix remodeling needed to resolve fibrosis, potentially contributing to progressive tissue stiffening.

Interactions

rs243865 is part of a three-SNP haplotype block with rs243864 and rs243866¹¹¹¹ rs243864 and rs243866
These three promoter variants are in high linkage disequilibrium with each other; the GTA haplotype at all three positions was significantly associated with percentage body fat in children. Individual SNP effects at rs243865 alone may underestimate the true haplotype effect. The MMP-2/TIMP-2 axis is directly relevant: high TIMP-2 (from rs7201 polymorphisms) combined with low MMP-2 (TT at rs243865) would compound the ECM remodeling deficit. The interaction between MMP-2 and MMP-3 (rs3025058) is particularly relevant for connective tissue health — both enzymes target the same basement membrane substrates and their combined activity determines net matrix turnover rate.

Supervisor note — candidate compound interaction: carriers of low-MMP-2 (TT at rs243865) combined with high-MMP-3 expression (TT at rs3025058, 5A/5A) represent a potentially destabilizing combination — reduced type IV collagen clearance from MMP-2 deficiency alongside elevated MMP-3 stromelysin activity. The net effect on connective tissue stability would depend on which substrates each enzyme preferentially targets in a given tissue context.

TERT (telomerase reverse transcriptase) is the catalytic subunit of telomerase, the enzyme that maintains telomere length by adding DNA repeats to chromosome ends. Telomeres shorten with each cell division¹¹ Telomeres shorten with each cell division
protective caps on chromosomes that prevent genomic instability, and when they reach a critical length, cells enter senescence or die. The rs2736100 variant sits in intron 2 of TERT at the 5p15.33 locus, a regulatory region that influences telomerase expression and activity. This common polymorphism reveals a fundamental paradox in human biology: the C allele promotes longer telomeres and increased cancer risk, while the A allele is associated with shorter telomeres and elevated risk of degenerative diseases.

The Mechanism

Rs2736100 is located within a putative regulatory region²² putative regulatory region
in the second intron of TERT at the 5p15.33 GWAS locus. Though the variant itself doesn't change the protein sequence (it's intronic, not in a coding region), it appears to influence TERT gene expression levels. Studies have shown that the C allele is associated with increased TERT mRNA expression³³ increased TERT mRNA expression
demonstrated in both normal and tumor lung tissues in lung epithelial cells. The variant may affect enhancer activity through allele-specific binding⁴⁴ enhancer activity through allele-specific binding
the DNA sequence shows differential affinity to nuclear proteins to transcription factors, modulating how much telomerase the cell produces. Higher telomerase activity maintains longer telomeres, which can be protective against age-related cellular dysfunction but also allows cancer cells more replicative potential.

The Evidence

The dual nature of rs2736100 is best illustrated by a comprehensive meta-analysis of 57 studies⁵⁵ comprehensive meta-analysis of 57 studies
encompassing cancer and non-cancer diseases published in 2018. Researchers found that the C allele was associated with increased cancer risk (pooled OR 1.16, 95% CI 1.09–1.23), while the same allele protected against non-cancerous degenerative diseases (pooled OR 0.81, 95% CI 0.65–0.99). Cancer associations are particularly strong for lung cancer, especially lung adenocarcinoma⁶⁶ lung cancer, especially lung adenocarcinoma
OR 1.54 in never-smoking Asian women, higher than European populations, glioma (P = 1.50 × 10⁻¹⁷), bladder cancer, thyroid cancer, and myeloproliferative neoplasms. Conversely, the A allele (shorter telomeres) is associated with increased risk of idiopathic pulmonary fibrosis⁷⁷ idiopathic pulmonary fibrosis
first disease association reported for this SNP (OR 1.82 for A allele), coronary artery disease, and other age-related conditions.

Mental Health and Telomere Biology

Recent research has uncovered connections between rs2736100 and mental health outcomes. A Ugandan study of HIV+ youth⁸⁸ Ugandan study of HIV+ youth
736 participants aged 5-17 years found that the GG genotype (equivalent to CC on the plus strand) moderated the relationship between internalizing mental disorders (depression, anxiety, PTSD) and telomere length attrition over 12 months. Among individuals with the GG genotype, those with internalizing disorders showed significantly longer baseline telomeres but accelerated shortening compared to controls — suggesting the variant influences how psychological stress affects cellular aging. A Swedish population study⁹⁹ Swedish population study
436 individuals with depression history, 1,590 controls reported that the rs2736100 minor allele (A, associated with shorter telomeres) was linked to depression diagnosis, but only among those without childhood adversity. This pattern suggests complex gene-environment interactions where the telomere-maintaining effects of different genotypes may interact with early life stress to influence mental health vulnerability.

Practical Implications

The evidence linking rs2736100 to both telomere length and disease risk is strong and replicated across multiple populations, but the clinical utility is nuanced. For CC carriers (longer telomeres), the increased cancer risk — particularly for lung adenocarcinoma, glioma, and myeloproliferative disorders — suggests heightened vigilance for early detection. However, the same genotype may offer protection against cardiovascular disease and pulmonary fibrosis. For AA carriers (shorter telomeres), the inverse applies: lower cancer risk but greater susceptibility to age-related degenerative conditions. AC heterozygotes fall in between, with intermediate telomere length and risk profiles.

From a mental health perspective, individuals carrying the A allele (especially AA homozygotes) may be at higher risk for depression, particularly in the absence of significant childhood trauma. This association appears to be mediated through telomere biology, as psychiatric disorders have been consistently linked¹⁰¹⁰ psychiatric disorders have been consistently linked
meta-analysis of 14,827 participants from 32 studies to accelerated telomere attrition. The mechanism likely involves chronic stress-related processes including inflammation, oxidative stress, and dysregulation of the hypothalamic-pituitary-adrenal axis, which cumulatively burden cells and drive telomere shortening.

Interactions

Rs2736100 is one of at least 11 SNPs that collectively influence leukocyte telomere length. It interacts most notably with variants in TERC (telomerase RNA component, rs10936599), which provides the RNA template for telomere synthesis, and variants affecting telomere stability such as OBFC1 rs9420907 and NAF1 rs7675998. A European study of myeloproliferative neoplasms¹¹¹¹ European study of myeloproliferative neoplasms
480 cases, 909 controls computed a "teloscore" combining these 11 SNPs and found that longer genetically determined telomeres (driven largely by rs2736100-C and OBFC1 rs9420907-C) increased MPN risk with OR 1.82 comparing highest to lowest quintile. The combined effect was greater than rs2736100 alone, suggesting additive or synergistic interactions between telomere-related variants.

For individuals with mental health concerns, the interaction between TERT rs2736100 and TERC rs16847897 warrants attention. The same Ugandan study found both SNPs moderated the depression-telomere relationship, with effects most pronounced in individuals carrying the CC genotype of TERC rs16847897 alongside specific TERT genotypes. While this interaction requires further validation in diverse populations, it suggests that telomerase genetics may partially explain individual differences in how mental health challenges affect biological aging.